Previous 10 | Next 10 |
BOSTON and JERUSALEM, Israel, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd . (NASDAQ: ENTX), today announced it has concluded its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on EB613, its oral formulation of human parathyroid hormone (1-34), or PTH, ...
Entera Bio (NASDAQ:ENTX): 9M GAAP EPS of -$0.68. Revenue of $0.41M (+192.9% Y/Y) Press Release For further details see: Entera Bio reports 9M results
‒ Two Presentations at ASB M R , including Late Breaker, on Phase 2 EB613 Clinical Trial Results in Osteoporosis ‒ ‒ Study Sets Stage for Phase 3 regist r ational trial in 2022 ‒ BOSTON and JER...
‒Study describes a dual mechanism of action approach to oral drug delivery of large molecules, the “Holy Grail” of drug development. ‒Technology is utilized in Entera’s EB613 oral PTH drug for osteoporosis and several other molecules now in dev...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Plowing through the most populated regions of the world like a hurricane, the novel coronavirus was and still is an unrelenting force. According to the time of writing data from Worldometers.info, 4.86 million people succum...
Increases in lumbar spine, femoral neck and total hip BMD demonstrated with EB613 Linear Dose Responses Seen in Biomarker and Bone Mineral Density Data Pivotal Phase 3 registration study expected to commence 2022 BOSTON and JERUSALEM, Oct. 06, 2021 (GLO...
The TransCon platform is designed to optimize the delivery of known drugs to target tissues. The valuation of Ascendis Pharma is largely a reflection of the potential of the platform rather than a sum of the parts figure based on the current pipeline assets. This $9.5 B market cap...
‒ Second of Two Presentations to be Delivered by Entera ‒ ‒ Final 6-Month Bone Mineral Density (BMD) Results Show Dose-Related Efficacy ‒ BOSTON and JERUSALEM, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in th...
BOSTON and JERUSALEM, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced it will host its annual shareholders meeting on Monday, October 4, 2021. About Entera Bio Entera...
BOSTON and JERUSALEM, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the Company’s CEO Spiros Jamas will present at the H.C. Wainwright 23rd Annual Global Investment Confer...
News, Short Squeeze, Breakout and More Instantly...